Why Is ALNYLAM PHARMACEUTIC (ALNY) Stock Down Today?
By the Top Tier Newswire AI Desk · October 30, 2026 at 12:11 AM ET · reviewed against 29 wire stories
ALNYLAM PHARMACEUTIC (ALNY) is down -25.13% in the latest session. Our newswire has captured 29 stories on ALNY across 9 sources in the last 36 hours, with AI sentiment reading mixed (avg 50/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Alnylam Pharmaceuticals shares fell 25.13% to $174.00 on October 29, 2026. The primary driver was the company's third-quarter earnings report, which revealed that product demand lagged expectations despite strong revenue growth.
What Happened
Alnylam reported total net product revenue of approximately $1.3 billion for the third quarter of 2026, representing a 52% year-over-year increase and a 10% quarter-over-quarter rise. The TTR franchise generated $1.15 billion in revenue, up 59% year over year. Despite these figures, management indicated that demand for AMVUTTRA lagged internal projections. The company also highlighted rising risks associated with 340B pricing. Alnylam maintained its target of $4.2 billion to $4.5 billion in total TTR sales for 2026. The firm expanded its Phase 3 TRITON-CM study for nucresiran to approximately 2,250 patients while keeping the launch timing for around 2030. Multiple law firms, including Glancy Prongay Wolke & Rotter LLP and The Law Offices of Howard G. Smith, announced they are investigating potential securities fraud following the stock decline.
What The Data Shows
The stock closed at $174.00, well below its 52-week high of $484.61 and near the lower end of its 52-week range of $197.81 to $484.61. The company currently has a market capitalization of $30.3 billion and a P/E ratio of 41.4. Trailing twelve-month revenue growth stands at 95.1%, with a net margin of 16.1%. The stock printed nine fresh 52-week highs and 24 fresh 52-week lows on October 29, 2026. Over the last eight sessions, the stock had already declined 17.2% from $230.71 to $191.12 before the final drop. Bryan Supran, Executive Vice President and Chief Legal Officer, sold shares on October 2, 2026. Recent congressional disclosures show three buys and two sells in the last 90 days, with the most recent filing on October 8, 2026.
What To Watch
Investors will monitor how the company manages the gap between reported revenue growth and underlying demand trends. The market will also watch for further developments in the TRITON-CM study and any updates to the 2030 launch timeline for nucresiran.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
AI sentiment, last 36h · averaged over 29 stories · 50/100 neutral
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
11h agoGlobeNewswireBEARISH 34General
Lost Money on Alnylam Pharmaceuticals, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Continues Investigating Possible Securities Fraud After 28.31% Share Price Drop
Investigation follows the July 30, 2026 disclosure regarding Alnylam Pharmaceuticals, Inc.; investors who lost money may have claims to recover their...
On October 29, 2026, Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) announced a robust 52% year-over-year increase in Q3 2026 product revenues, reaching approximate
12h agoGlobeNewswireBEARISH 34General
Did You Lose Money on Alnylam Pharmaceuticals, Inc. Stock? The Law Offices of Howard G. Smith Continues Securities Fraud Investigation After 28.31% Share Price Decline
Investigation comes after a July 30, 2026 report concerning Alnylam Pharmaceuticals, Inc.; shareholders who suffered losses may have claims to recover...
Total Net Product Revenue: ~$1.3 billion, up 52% YoY and 10% QoQ (incl. FX impact).TTR Franchise Revenue: $1.15 billion, up 59% YoY and 12% QoQ.US TTR Revenue:
13h agoGlobeNewswireBEARISH 34General
Lost Money on Alnylam Pharmaceuticals, Inc. Shares? The Law Offices of Frank R. Cruz Continues Investigating Potential Securities Fraud After 28.31% Stock Decline
Investigation centers on the July 30, 2026 news about Alnylam Pharmaceuticals, Inc.; investors with losses may have potential claims to recover them...
15h agoSeeking AlphaBULLISH 58Earnings
Alnylam anticipates $4.2B–$4.5B 2026 TTR sales, expands TRITON-CM to ~2,250 patients while keeping ~2030 launch timing
Alnylam Q3 2026 earnings: AMVUTTRA drove 52% growth, but demand lagged and 340B risks rose.
15h agoSeeking AlphaNEUTRAL 50Earnings
Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2026 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2026 Earnings Call October 29, 2026 8:30 AM EDTCompany ParticipantsJoshua Brodsky - Vice President of Investor...
16h agoThe Motley FoolBULLISH 74Earnings
Alnylam (ALNY) Q3 2026 Earnings Call Transcript
AMVUTTRA revenue jumped 65% year over year as TTR franchise momentum accelerates.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →